AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03646123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 by IV infusion
Study NCT03646123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
Study NCT00651976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Take by mouth at a dose of 2.5 mg on days 7-21
Study NCT00651976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
Study NCT00651976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy/lumpectomy/mastectomy
Description: Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
Study NCT03252496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
Study NCT03252496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Bupivacaine
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Fentanyl
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Study NCT03252496 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean Delivery
Description: Lower segment cesarean section using the Pfannenstiel incision
Study NCT03252496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Delivery
Description: Lower segment cesarean section using the Pfannenstiel incision
Study NCT03252496 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound Assessment of the Inferior Vena Cava
Description: The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
Study NCT03252496 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Assessment of the Inferior Vena Cava
Description: The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mL Colloid over 5 minutes
Description: 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 250 mL Crystalloid over 5 minutes
Description: Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mL Crystalloid over 55 minutes
Description: Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mL Crystalloid over 55 minutes
Description: Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mL Colloid over 60 minutes
Description: After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 250 mL Crystalloid over 60 minutes
Description: After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ephedrine
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ephedrine
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Syntocinon
Description: Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
Study NCT03252496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Syntocinon
Description: Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
Study NCT01881594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure/Surgery
Description: daily stimulation of efferent loop prior to surgery (ileostomy closure)
Study NCT01881594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery
Description: daily stimulation of efferent loop prior to surgery (ileostomy closure)
Study NCT04059445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)
Description: Regenerative therapy with biphasic calcium phosphate + collagen membrane.
Study NCT04059445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)
Description: Regenerative therapy with biphasic calcium phosphate + collagen membrane.
Study NCT03646123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 240 mg by IV infusion
Study NCT00039455 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00039455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00039455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00039455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00918957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
Study NCT00918957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
Study NCT06165185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Please see the associated arm description
Study NCT06165185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Please see the associated arm description
Study NCT06165185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Please see the associated arm description
Study NCT00938535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention
Description: This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
Study NCT01437358 — intervention group
Intervention type: OTHER
Intervention: Epidural analgesia
Description: The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
Study NCT00793754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 100 mg / day for 8 weeks
Study NCT00793754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40 mg / day for 8 weeks
Study NCT00793754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin + Atorvastatin
Description: Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
Study NCT03804086 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement
Description: will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~* The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~* After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze.
Study NCT04059445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Description: Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
Study NCT04059445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Description: Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
Study NCT02848300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 1% Formulation A
Description: Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
Study NCT02848300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 1% Formulation B
Description: Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
Study NCT01208038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrinsa Transdermal testosterone patch
Description: 300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
Study NCT01769079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate
Description: Two arms: placebo and nitrate
Study NCT01769079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02218658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WE941 OD tablets
Study NCT02218658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brotizolam
Study NCT02499003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab and Pixantrone
Description: Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
Study NCT03086200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief Motivational Interviewing
Description: All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule.
Study NCT03804086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement
Description: a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
Study NCT00332644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: used according to FDA package label
Study NCT03350945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: tumor localization
Description: At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
Study NCT03350945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: tumor localization
Description: At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
Study NCT00332644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine lozenge
Description: used according to FDA-approved package directions
Study NCT00332644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch + nicotine lozenge
Description: dosage of both according to FDA-approved dosing schedule
Study NCT00878657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
Study NCT04768244 — intervention group
Intervention type: OTHER
Intervention: maternal SARS-CoV-2 infection
Description: positive PCR in nasopharinx and/or presence of antibodies in serum
Study NCT02150746 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral/Central Venous Blood Draw
Description: Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
Study NCT02150746 — intervention group
Intervention type: PROCEDURE
Intervention: Peritoneal Wash
Description: Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
Study NCT04089410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermic Fitness Treatment (HFT)
Description: The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.
Study NCT04089410 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Hyperthermic Fitness Treatment
Description: Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.
Study NCT04089410 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Examination
Description: Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand.
Study NCT00332644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: dosage according to FDA-approved instructions
Study NCT00332644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion + lozenge
Description: dosage according to FDA approved standard instructions
Study NCT00332644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dosage same as active drug conditions
Study NCT02823548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droglican
Description: Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
Study NCT02823548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01693419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GES (Gemcitabine, Erlotinib, S-1)
Description: Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m² IV on day 1, 8~2. Erlotinib 100 mg/day PO on day 1~3. S-1 60 mg/m²/day PO on day 1-14
Study NCT02614560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)
Study NCT02614560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 intravenously, 2 days before the transplant
Study NCT02614560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadastuximab talirine
Description: Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant
Study NCT02614560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadastuximab talirine
Description: Post-allo (after stem cell transplant) given on Day 1 of each cycle
Study NCT03587363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive 6 mg (2\*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
Study NCT03182959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avmacol®
Description: Avmacol® tablets
Study NCT00419094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra XR
Description: Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
Study NCT00419094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra XR
Description: Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
Study NCT04375449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pep2dia
Description: what is the effect of Pep2dia on postprandial glycemia after a meal rich in carbohydrates (75g)
Study NCT04375449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin
Study NCT02253719 — intervention group
Intervention type: PROCEDURE
Intervention: cryotherapy, further biopsy, LEEP, surgery as indicated
Description: These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
Study NCT00839046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Worker Intervention
Description: The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
Study NCT00878657 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy
Study NCT02813798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivipansel
Description: A single 840mg dose of Rivipansel over 20 minutes